Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update
Target population These recommendations apply to adult patients with recurrent WHO grade
2 infiltrative diffuse glioma (oligodendroglioma, astrocytoma). Questions and …
2 infiltrative diffuse glioma (oligodendroglioma, astrocytoma). Questions and …
The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma
J Zhu, Q Lin, H Zheng, Y Rao, T Ji - Frontiers in Oncology, 2022 - frontiersin.org
Background Glioma is an incurable malignant lesion with poor outcome characterized by
easy recurrence after surgery with or without radiotherapy and chemotherapy. Studies have …
easy recurrence after surgery with or without radiotherapy and chemotherapy. Studies have …
Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625
JL Boxerman, BS Snyder, DP Barboriak… - Frontiers in …, 2023 - frontiersin.org
Background Progressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625,
a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent …
a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent …
Bevacizumab in recurrent WHO grades II–III glioma
S Annakib, V Rigau, A Darlix, C Gozé, H Duffau… - Frontiers in …, 2023 - frontiersin.org
Purpose The management of recurrent WHO grades II–III (rGII–III) glioma is not well
established. This study describes the clinical outcomes in patients who received …
established. This study describes the clinical outcomes in patients who received …
Prognostic value and drug sensitivity of F‑box and leucine‑rich repeat protein 6 in glioma
Q Lin, J Zhu, W Zhu, H Zhu, M Li, J Zhao… - Oncology …, 2024 - spandidos-publications.com
Gliomas are highly malignant and invasive tumors lacking clear boundaries. Previous
bioinformatics and experimental analyses have indicated that F‑box and leucine‑rich repeat …
bioinformatics and experimental analyses have indicated that F‑box and leucine‑rich repeat …
Late-line treatment with bevacizumab alone or in combination with chemotherapy in recurrent high-grade gliomas
M Yahia-Cherif, S Luce, O De Witte… - Acta …, 2023 - Springer
Purpose Bevacizumab's use in recurrent high-grade glioma is controversial. This study
evaluates outcomes in recurrent high-grade glioma patients receiving bevacizumab alone or …
evaluates outcomes in recurrent high-grade glioma patients receiving bevacizumab alone or …
Synergistic therapies for recurrent malignant Gliomas
JE Simon, VC Prabhu, K Barton, E Borys… - World …, 2020 - pubmed.ncbi.nlm.nih.gov
Synergistic Therapies for Recurrent Malignant Gliomas Synergistic Therapies for Recurrent
Malignant Gliomas World Neurosurg. 2020 Jan:133:237-239. doi: 10.1016/j.wneu.2019.10.033 …
Malignant Gliomas World Neurosurg. 2020 Jan:133:237-239. doi: 10.1016/j.wneu.2019.10.033 …
Prognostic value and drug sensitivity of FBXL6 in glioma
Q Lin, J Zhu, W Zhu, H Zhu, M Li, J Zhao, S Jia, S Nie - 2023 - researchsquare.com
Purpose Gliomas are highly malignant and invasive tumors that lack clear boundaries.
Recent bioinformatics and experimental analyses have indicated that FBXL6, a protein …
Recent bioinformatics and experimental analyses have indicated that FBXL6, a protein …
A Systematic Review on Efficiency & Effectiveness of Combined drug and therapy with Bevacizumab in Glioblastoma
SI Shommo - 2022 - dspace.bracu.ac.bd
The most frequent and deadly primary malignant cerebral tumor in adults is glioblastoma
(GBM). The US Food and Drug Administration has licensed Bevacizumab (BEV) for the …
(GBM). The US Food and Drug Administration has licensed Bevacizumab (BEV) for the …